The global facial injectable market size was valued at US$ 12.25 billion in 2021 and is expected to hit US$ 28.13 billion by 2030 and poised to grow at a CAGR of 9.7% during the forecast period 2021 to 2030.
The dermal fillers often known as facial injectables, are treatments that help with facial rejuvenation. These injectable face solutions are primarily intended to alleviate early indicators of ageing such as wrinkles and to enhance aesthetic appearance.
There has been a significant growth in disposable incomes worldwide, as well as rise in aesthetic attractiveness consciousness. As a result, as more people choose to improve their physical appearances, attitudes around cosmetic operations have shifted. A growing number of people are choosing for minimally invasive procedures like facial injectables since they are considered safer and require little to no delay. The neurotoxins like botulinum toxin as well as dermal fillers like hyaluronic acid and calcium hydroxylaptite are among the facial injectables available in the market.
The need for cosmetic procedures is being driven by an increase in the number of plastic surgeons and their networks, which is in turn increasing the demand for facial injectables. There was also Food & Drug Administration (FDA) authorization for other practitioners including as surgeons to utilize facial injectable in their clinics. The healthcare practitioners can now perform facial injectable procedures because they encounter many patients requiring facial transformation after dental treatments. The facial injectable market is likely to develop as a result of this factor.
Report Scope of the Facial Injectable Market
|Market Size by 2030||USD 28.13 Billion|
|Growth Rate from 2022 to 2030||
CAGR of 9.7%
|Largest Market||North America|
|Fastest Growing Market||Asia Pacific|
|Forecast Period||2022 to 2030|
|Segments Covered||Product, Application, End User, Generation, Geography|
|Companies Mentioned||Johnson & Johnson, Syneron Candela, Lumenis, Hologic, Solta Medical, Alma Laser, Galderma, Dickinson and Company, Antares Pharma, Novartis AG|
The facial injectable market is primarily driven by the surge in demand for aesthetic attractiveness enhancement and a preference for minimally invasive procedures. Furthermore, the facial injectable market is expected to develop due to an increase in the senior population and the advent of improved facial injectables such as synthetic calcium hydroxylaptite (CaHA) fillers. On the other hand, severe regulatory frameworks about injectable medications, as well as side effects including rashes, limit the growth of the facial injectable market during the forecast period.
The cosmetics sector is thriving in the current decade, with an estimated rapid expansion during the forecast period. The total number of non-surgical procedures such as dermal filler injections and wrinkle relaxer has increased since few decades. This development is mostly due to technological advantages such as quick recovery, less blood loss, reduced infection risk, reduced infection risk, and lower overall procedure costs. Thus, the facial injectable market has grown as the number of cosmetic treatments has increased during the forecast period.
The encouraging trends in the use of cosmetic injectables have prompted more notable corporations to become involved. These companies have engaged in a variety of research and development projects in order to develop novel fillers that fulfil unsatisfied customer needs. This has resulted in the introduction of new products as well as a rise in procedure volumes around the world. Such positive factors are projected to have a significant impact on the facial injectable market growth throughout forecast period. Another important market trend that is predicted to boost the facial injectable market expansion is the increased use of these kind of products by people of all ages.
The mergers, collaborations, partnerships, and agreements between facial injectable manufacturers are boosted by increasing demand for facial injectables, positive government assistance in terms of product approval for new application areas, and commercialization of unique solutions in the facial injectable market. Due to the rise in cosmetic tourism across Asia-Pacific, cosmetic product manufacturers are always concentrating on expanding their product reach.
As a result, corporations are turning to distribution partnerships as a means of increasing revenue from the facial injectable sector. To exploit new markets and give patients a competitive advantage, some significant market players are cooperating with various aesthetic companies other than facial injectable providers.
Thus, the expanding aesthetic consciousness and number od cosmetic operations, the development of cost effective facial injectables, and the ageing population are all factors driving the growth of the facial injectable market during the forecast period.
The botulinum toxin Type A segment dominated the facial injectable market in 2021 with a 55% of revenue share. To reverse the effects of ageing, middle aged women are increasingly turning to injectables and fillers, such as botulinum toxin Type A.
The hyaluronic acid (HA) segment is fastest growing segment in 2021 and will reach 9.7% CAGR over the forecast period. The hyaluronic acid (HA) is well-known for its capacity to retain moisture in the skin, making it appear healthier. The hyaluronic acid contains a moisture binding property that aids in the enhancement and maintenance of the necessary moisture that keeps the skin plump.
In 2021, the aesthetics segment dominated the facial injectable market with a revenue share of 72%. The increased usage of facial injectables for aesthetic operations such as lip lines, facial lines, and wrinkles on the face has fueled the expansion of the segment.
The therapeutic segment, on the other hand, is predicted to develop at the quickest rate in the future years. This is due to growing use of facial injectables to treat focal hyperhidrosis, blepharospasm and strabismus.
North America accounted revenue share of 42% in 2021. The huge senior population in the U.S. and Canada is expected to drive demand for facial injectables over the projected period. The new product launches by key market players in North America is also driving the growth of the market during the forecast period.
Asia-Pacific, on the other hand, is expected to develop at the fastest rate 10% during the forecast period. In the developing nations of Asia-Pacific, a growing emphasis on physical beauty is projected to drive demand for face injectable treatment in the region over the projection period.
The facial injectables market is moderately fragmented with the presence of several companies. These market players are striving to gain higher market share by adopting different marketing strategies, such as new product launch, investments, partnerships, and mergers & acquisitions. The companies are also spending on the development of improved products. Moreover, they are also focusing on competitive pricing.
Some of the prominent players in the global facial injectable market include:
Segments Covered in the Report
No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client